Dupixent MDL 3180 Reaches Its First Case Management Conference With the Docket Still Growing

Dupixent MDL 3180 — the federal products liability litigation alleging that the atopic dermatitis biologic dupilumab causes, accelerates or unmasks cutaneous T-cell lymphoma — reaches its first substantive procedural milestone on 1 October 2026, when Judge Zahid N. Quraishi holds the initial case management conference in the District of New Jersey. The Judicial Panel on Multidistrict Litigation created the docket on 4 June 2026 with 15 transferred actions drawn from 12 districts; by early September the count had roughly doubled, and complaints are still being filed, including one lodged in the District of Connecticut on 16 September 2026 and reported on 24 September.

That arithmetic is the story. A Multidistrict Litigation (MDL) that opens at 15 actions and reaches the mid-thirties before its first conference is not a docket that has found its ceiling; it is a docket that has not yet found its floor. What Judge Quraishi decides on 1 October — leadership, the shape of common discovery, whether there is a census, how plaintiff fact sheets work — will determine how quickly the next several hundred claims arrive and how much they cost to process.

What is the Dupixent MDL and where is MDL 3180 pending?

MDL No. 3180, captioned In re: Dupixent (Dupilumab) Products Liability Litigation, is pending in the U.S. District Court for the District of New Jersey before Judge Zahid N. Quraishi. It consolidates federal actions alleging that Regeneron Pharmaceuticals, Inc., Sanofi-Aventis U.S. LLC and Genzyme Corporation failed to warn patients and prescribers that Dupixent may cause, accelerate or conceal cutaneous T-cell lymphoma (CTCL), a group of non-Hodgkin lymphomas whose commonest forms are mycosis fungoides and Sézary syndrome.

The procedural path was short by mass tort standards. Plaintiffs moved the Judicial Panel on Multidistrict Litigation (JPML) for centralization under 28 U.S.C. § 1407 on 13 February 2026. The Panel heard the motion and issued its transfer order on 4 June 2026, sending 15 pending actions filed across 12 federal districts to New Jersey and identifying a further seven potential tag-along actions. Fewer than four months elapsed between motion and order — fast, and a signal that neither side thought the question of whether to centralize was genuinely contested.

The Panel's stated common questions are the ordinary triad of a pharmaceutical Mass Tort: whether Dupixent can cause or accelerate CTCL, when the manufacturers knew or should have known of that risk, and whether the warnings they gave were adequate. Those are questions of General Causation, corporate knowledge, and Failure to Warn respectively, and each will consume its own phase of the litigation.

One point that the consumer-facing coverage of this litigation repeats, correctly, is worth restating in practitioner terms: an MDL is not a Class Action. Centralisation under § 1407 is a pretrial coordination device. Each transferred plaintiff retains an individual claim, individual damages, and — absent a waiver — a right to remand to the transferor court for trial. Nothing about MDL 3180 binds an absent Dupixent user, and nothing about it produces a common fund by operation of law.

What happens at the Dupixent MDL's first case management conference on October 1, 2026?

The initial case management conference is where an MDL acquires its architecture. On 11 June 2026, a week after transfer, Judge Quraishi directed the parties to confer and attempt agreement on threshold matters ahead of a 24 July 2026 deadline, then set the conference for 1 October 2026. The parties filed a joint management report on 10 September 2026 addressing plaintiff leadership, discovery, scheduling, future conferences and the basic structure of the litigation, and are to prepare a proposed initial management order by 1 November 2026.

Practitioners reading the docket for the first time should expect the conference to address, in some order, the following:

• Leadership. Appointment of plaintiffs' lead and liaison counsel, an executive committee, and a science or law-and-briefing subcommittee. Applications are ordinarily due before the conference; the composition chosen here will control the litigation's tempo for years.
• Common benefit. Establishment of a Common Benefit Fund and the holdback percentage on recoveries, together with time-and-expense submission protocols. Early common benefit orders are among the most consequential and least reviewed rulings an MDL judge makes.
• Case-initiating discovery. A Plaintiff Fact Sheet (PFS) and a Defendant Fact Sheet (DFS), their deadlines, and the consequences of non-compliance. In a litigation whose central factual question is the sequence of diagnosis — atopic dermatitis first, or lymphoma all along — the PFS will need to capture biopsy dates, dermatopathology reports, prescriber identity and the full treatment history before and after the first Dupixent injection.
• A Census Registry. Whether unfiled claims are to be registered rather than filed, and on what tolling terms. A census is the standard modern answer to a docket that is growing faster than the court can docket it, and this docket is growing.
• Direct filing. Whether plaintiffs may file directly into the MDL, and what waiver of Lexecon rights, if any, that entails.
• ESI and custodial discovery. Search terms, custodian lists, and the treatment of pharmacovigilance databases and regulatory correspondence — the documents that will determine whether the knowledge case is provable.
• Science day. A tutorial for the court on T-helper-2 immunology, the natural history of mycosis fungoides, and the diagnostic overlap between severe atopic dermatitis and early-stage CTCL. In a case whose defense is that the drug revealed rather than caused the disease, science day is not a formality.

What will almost certainly not be decided on 1 October is a Bellwether Trial pool or a trial date. Those follow leadership and core discovery, usually by twelve to twenty-four months in a docket of this size.

How many Dupixent lawsuits are pending in MDL 3180?

The reported counts form a consistent upward series, though the sources differ on the exact figure at any given moment because the JPML's statistics reports, the district docket and secondary trackers are each measuring slightly different things at slightly different times.

Date	Reported pending actions	Source basis
13 February 2026	Motion for transfer filed	JPML § 1407 motion
4 June 2026	15 transferred, 7 potential tag-alongs, from 12 districts	JPML transfer order
1 July 2026	26	JPML statistics report
Early August 2026	28	JPML pending-MDL report of 3 August 2026
Early September 2026	approximately 35	Secondary docket reporting
16 September 2026	New complaint filed in D. Conn.	Complaint reported 24 September 2026

Two observations follow. First, the growth rate — roughly a doubling in the quarter after centralization — is the ordinary profile of a drug MDL in its recruitment phase, not evidence of an unusually strong case. Second, at roughly 35 actions, MDL 3180 remains small. It is smaller than the Depo-Provera docket by two orders of magnitude and smaller than the Ozempic NAION litigation. The question the 1 October conference implicitly answers is whether the court builds infrastructure for 35 cases or for 3,500.

The commercial denominator argues for the latter. Dupixent recorded global net sales of $17.8 billion in 2025, a 26% increase over 2024, and $4.9 billion in the first quarter of 2026 alone, up 33%. A drug with that exposure across atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, COPD and bullous pemphigoid generates a claimant pool that is limited by diagnosis rates and attorney advertising, not by prescription volume.

Inside the transfer order: the venue fight and the scope the Panel did not give plaintiffs

Two features of the 4 June 2026 transfer order deserve more attention than they have received, because both shape filing strategy now.

The first is venue. Regeneron and Sanofi did not resist centralization; they resisted New Jersey, urging the Southern District of New York instead. The fight was therefore never about whether coordinated proceedings were appropriate, but about which bench would run them. Plaintiffs prevailed, and the practical consequence is a transferee judge in the district where Sanofi-Aventis U.S. LLC has its principal domestic operations — convenient for document custodians and corporate witnesses, and situated in a circuit whose products liability jurisprudence plaintiffs generally prefer to the Second Circuit's.

The second is scope, and it is the more consequential. The Panel centralized claims alleging cutaneous T-cell lymphoma. It did not sweep in every T-cell malignancy alleged against dupilumab. Instead it indicated that actions involving non-cutaneous T-cell lymphomas — peripheral T-cell lymphoma, anaplastic large cell lymphoma and their relatives — may be brought in later through the conditional transfer order process on a case-by-case basis.

That is a narrower grant than the moving plaintiffs sought, and it has three effects. It keeps the general causation inquiry disciplined around a single disease with a coherent biological hypothesis, which helps plaintiffs at the Daubert Challenge stage. It leaves counsel holding a non-cutaneous lymphoma claim with a choice between filing in the home district and waiting for a conditional transfer order, or filing directly into New Jersey and inviting a vacatur motion. And it gives defendants an argument, already visible on the horizon, that any attempt to expand the MDL's disease definition is an attempt to relitigate the Panel's order rather than to amend a pleading.

Does the Dupixent label warn about cutaneous T-cell lymphoma?

No. The approved United States prescribing information for Dupixent does not carry a warning about cutaneous T-cell lymphoma, lymphoma or malignancy, and Dupixent has not been recalled or restricted. That single fact is the spine of the litigation.

What exists instead is a regulatory signal without a corresponding label change. In March 2025, following review of adverse event data reported through the FDA Adverse Event Reporting System (FAERS), the FDA added dupilumab to its quarterly list of drugs with potential signals of serious risk for T-cell lymphoma and stated that it was evaluating the need for regulatory action. As of the summer of 2026 that evaluation had not produced a labeling change.

For plaintiffs, that gap is the case: a manufacturer on notice of a signal the regulator itself found worth listing, a label that says nothing, and a prescribing population — dermatologists treating refractory eczema — who would plainly have wanted to know. It supports a conventional Failure to Warn theory and, under the Learned Intermediary Doctrine, focuses the inquiry on what the treating dermatologist would have done differently had a warning existed. Because the population at issue is one in which biopsy is the diagnostic answer, the counterfactual is unusually concrete: a warning would have prompted earlier biopsy, and earlier biopsy in mycosis fungoides is the difference between patch-stage disease and tumor-stage disease.

For defendants, the same gap is the defense. Preemption (Products) arguments in branded drug cases turn on whether the manufacturer could unilaterally have strengthened the label under the changes-being-effected regulation and whether there is clear evidence the FDA would have rejected the change. A regulator that has had the signal in front of it since March 2025, has said it is evaluating regulatory action, and has not required a warning, is a regulator whose inaction defendants will characterize as a considered judgment. Whether that characterisation survives depends on documents — what the companies told the agency, and when — that will not surface until custodial discovery is well advanced.

Several details a practitioner would want are not available from public reporting and are not asserted here: the precise revision date and Warnings and Precautions inventory of the current label, the exact content of any FDA correspondence, and whether the companies have submitted a labeling supplement. Those belong in the first round of regulatory discovery, not in a news summary.

Does Dupixent cause cutaneous T-cell lymphoma, or unmask it?

This is the fight, and it is a genuine one. The published literature supports an association; the mechanism behind the association is contested.

Evidence	Finding	Significance
Retrospective cohort study, Journal of the American Academy of Dermatology (2024)	Odds ratio 4.10 (95% CI 2.055–8.192) for CTCL among atopic dermatitis patients treated with dupilumab; risk persisted after excluding prior disease-modifying antirheumatic drug use; no increase for other cutaneous or lymphoid malignancies	The single most citable epidemiological result for plaintiffs; the disease-specificity undercuts a general-immunosuppression confounder
FAERS pharmacovigilance analysis (published 2024)	113 CTCL reports, about 0.1% of dupilumab-related FAERS reports; adjusted reporting odds ratio 8.81 (95% CI 7.1–10.9); signal restricted to patients treated for atopic dermatitis, absent in non-dermatological indications	Disproportionality signal, not incidence; the indication-restriction cuts both ways
Case series of 18 patients, JAAD	Among patients treated with dupilumab for presumed atopic dermatitis, 33% developed erythroderma and 22% developed tumors after exposure	Supports an acceleration theory rather than initiation
Commentary, American Journal of Clinical Dermatology (2025), and related Journal of Investigative Dermatology analysis	Association is multifactorial; calls for vigilance rather than alarm; unmasking of pre-existing, misdiagnosed CTCL is a leading explanation	The defense's core literature
Immunotranscriptomic work, Journal of Allergy and Clinical Immunology	Proposes a mechanism by which dupilumab's action on the T-helper-2 pathway could permit unmasking or progression of cutaneous lymphoma	A mechanism paper that both sides will claim

The unmasking hypothesis runs as follows. Early mycosis fungoides is notoriously difficult to distinguish from severe atopic dermatitis; patients are treated as eczema patients, fail first-line therapy, are escalated to dupilumab, fail again, and are finally biopsied — at which point the lymphoma that was there all along is diagnosed. On that account, dupilumab is a marker of diagnostic difficulty rather than a cause of disease, and the observed association is confounding by indication in its purest form.

Plaintiffs have two answers. The first is the disease-specificity in the cohort data: if dupilumab merely flagged hard-to-diagnose skin disease, one would expect elevated detection of other cutaneous malignancies too, and the cohort study reports none. The second is acceleration: even if some proportion of CTCL was present before the first injection, blocking the T-helper-2 axis in a patient with occult cutaneous lymphoma may accelerate progression to erythroderma and tumor stage — an injury in its own right, and one the case series is consistent with.

Neither answer resolves Specific Causation for an individual claimant, and that is where this litigation will ultimately be won or lost. A plaintiff whose first Dupixent injection preceded diagnosis by three months faces a harder acceleration argument than one with four years of exposure. Expect defendants to press temporal-proximity arguments hard at the plaintiff fact sheet stage, and expect a Lone Pine Order motion in due course.

Two tracks: the September 16 Connecticut complaint and the Maryland class action

The docket is not moving in one direction only, and the newest filings show two distinct theories running in parallel.

The individual personal injury track is illustrated by the complaint filed on 16 September 2026 in the U.S. District Court for the District of Connecticut and reported on 24 September, brought by a plaintiff named Anna Tsang against Regeneron Pharmaceuticals, Inc., Sanofi-Aventis U.S. LLC and Genzyme Corporation. The complaint alleges that she used Dupixent for only a few months before being diagnosed with a rare T-cell lymphoma, that the scientific data on cancer risk was available before she was first prescribed the drug, and that the manufacturers withheld it from consumers and the medical community to protect revenue across the product's many approved indications. It also pleads a failure to investigate — that the companies continued marketing without conducting the testing the evidence should have prompted. As a filed federal action alleging CTCL, it is a natural tag-along candidate for conditional transfer into MDL 3180.

The second track is economic rather than personal injury, and it is the piece of this litigation that the top-ranking coverage misses entirely. Regeneron's Form 10-Q for the quarterly period ended 30 June 2026 discloses that on 17 July 2026 two plaintiffs filed a putative class action in the U.S. District Court for the District of Maryland alleging that the company failed to warn that Dupixent causes or is linked to the development of cutaneous T-cell lymphoma. The same disclosure confirms the federal and state personal injury actions, the 13 February 2026 JPML motion and the 4 June 2026 transfer order.

A consumer class action alongside a personal injury MDL is a familiar pairing, and it matters for three reasons. It creates a second forum in which the same warnings record will be litigated, on a Rule 23 timetable rather than a bellwether timetable. It raises the prospect of overlapping discovery and of a JPML tag-along fight over whether an economic-loss class claim belongs in a personal injury MDL at all. And it changes the settlement geometry: a defendant contemplating resolution of CTCL injury claims must also price a class of purchasers who allege they would not have paid for the drug, or would have paid less, had the label said what they say it should have said.

Who qualifies to file a Dupixent lymphoma lawsuit, and what is the filing deadline?

The claim profile being filed is a plaintiff who used dupilumab — most often for atopic dermatitis — and was subsequently diagnosed with cutaneous T-cell lymphoma, mycosis fungoides or Sézary syndrome. Wrongful death claims arising from lymphoma deaths after treatment are also being pleaded. Claims involving non-cutaneous T-cell lymphomas exist but sit outside the MDL's defined scope and reach New Jersey, if at all, through the conditional transfer process.

The evidentiary core of a viable claim is documentary: proof of dupilumab exposure (pharmacy records, prescriber records, injection dates) and dermatopathology establishing the lymphoma diagnosis and its stage. The dates matter more here than in most drug cases, because the unmasking defense is a defense about sequence.

There is no single national filing deadline. The Statute of Limitations is set by state law and is commonly two years for personal injury — 42 Pa. C.S. § 5524 in Pennsylvania and N.J.S.A. 2A:14-2 in New Jersey are the examples most often cited in this litigation — with other states running from two to six years. The Discovery Rule is what usually saves an older claim: in most jurisdictions the period begins when the plaintiff knew, or reasonably should have known, both of the injury and of its causal connection to the product. In a litigation where the alleged injury is a cancer that was long treated as eczema, and where the drug's label still says nothing about lymphoma, the accrual argument is unusually favourable to plaintiffs. It is not automatic, and a Statute of Repose in a handful of states cuts off claims regardless of discovery.

Counsel holding unfiled claims should watch the 1 October conference for whether a census registry with a Tolling Agreement emerges. If it does, the calculus for filing versus registering changes immediately.

When will Dupixent bellwether trials or a settlement happen?

There is no bellwether schedule, no trial date and no settlement framework in MDL 3180, and none is likely to issue on 1 October. The realistic sequence, based on how comparably sized pharmaceutical MDLs have run, is leadership and structural orders in late 2026, core corporate and regulatory discovery through 2027, general causation expert work and a Daubert Challenge in 2028, and bellwether trials no earlier than 2029 absent an unusual acceleration.

Any settlement figure circulating now is speculation. There has been no verdict, no Daubert ruling, no bellwether, and no Settlement Matrix. Claim values in a CTCL litigation would ultimately turn on stage at diagnosis, the interval between first exposure and diagnosis, treatment burden, and whether the case is a progression case or an initiation case — distinctions that do not exist until a court has ruled on general causation.

The variable most likely to compress that timeline is not the litigation at all. It is the FDA. A labeling change adding a lymphoma warning would remove the manufacturers' strongest preemption argument prospectively while validating the plaintiffs' central premise retrospectively, and would almost certainly be followed by a step-change in filings. A formal agency determination that the evidence does not support a warning would do the opposite.

What it means for plaintiffs' firms, defense counsel, and claimants

For plaintiffs' firms. Leadership applications are the immediate work; the executive committee seated in New Jersey will run this litigation. Firms holding inventory should be building dermatopathology-complete files now rather than after a plaintiff fact sheet order lands, because the PFS in this litigation will demand biopsy-level detail that takes months to collect. The disease-scope limit in the transfer order means non-cutaneous lymphoma inventory needs a separate filing plan. And the pending Maryland class action is a reason to think carefully before pleading economic loss counts alongside personal injury counts in an MDL complaint.

For defense counsel. The preemption record is being made now, in regulatory correspondence, not later in briefing. The unmasking defense is scientifically respectable and will be well supported in the literature, but it is a specific causation defense dressed as a general causation defense, and it works case by case rather than across the docket — which argues for early, aggressive use of fact sheet deficiency practice and, eventually, a Lone Pine Order. The venue loss in New Jersey is a fact to be managed rather than relitigated.

For claimants and treating physicians. Nothing in MDL 3180 is a finding that Dupixent causes cancer; the Panel decided only that the claims share enough common questions to be coordinated. The drug remains approved, unrestricted and, for many patients, effective. The practical point from the litigation record is narrower and clinically sensible: atopic dermatitis that behaves atypically, or that fails to respond as expected to a targeted biologic, is a reason for biopsy.

For funders and case acquirers. This is an early-stage docket with an unresolved general causation question, no bellwether visibility, and a regulatory decision pending that could move valuations sharply in either direction. The asymmetry is real in both directions, which is a different proposition from a mature MDL with a settlement matrix.

Frequently asked questions

What is MDL 3180?

MDL No. 3180 is In re: Dupixent (Dupilumab) Products Liability Litigation, a federal multidistrict litigation created by the JPML on 4 June 2026 and assigned to Judge Zahid N. Quraishi in the District of New Jersey. It coordinates pretrial proceedings in actions alleging that Regeneron, Sanofi-Aventis U.S. LLC and Genzyme failed to warn that Dupixent may cause, accelerate or unmask cutaneous T-cell lymphoma.

When is the first Dupixent MDL case management conference?

1 October 2026, before Judge Quraishi in Newark. The parties filed a joint management report on 10 September 2026 and are to prepare a proposed initial management order by 1 November 2026.

Is the Dupixent MDL a class action?

No. Centralisation under 28 U.S.C. § 1407 coordinates pretrial proceedings; every plaintiff keeps an individual claim and individual damages. There is a separate putative class action, filed by two plaintiffs in the District of Maryland on 17 July 2026, disclosed in Regeneron's Form 10-Q for the period ended 30 June 2026.

How many Dupixent lawsuits have been filed?

The MDL opened with 15 transferred actions on 4 June 2026. The Panel's statistics reported 26 pending actions at 1 July 2026 and 28 in early August; secondary reporting put the figure at roughly 35 by early September 2026, with new complaints continuing to be filed.

Does Dupixent's label warn about lymphoma?

It does not. The FDA added dupilumab to its list of drugs with potential signals of serious risk for T-cell lymphoma in March 2025 and said it was evaluating the need for regulatory action, but no lymphoma or cutaneous T-cell lymphoma warning has been added to the approved prescribing information, and the drug has not been recalled.

When will there be a Dupixent settlement?

There is no settlement, no settlement framework and no bellwether trial date. Given that general causation expert work has not begun, a resolution before the end of the decade would be unusually fast for a litigation at this stage.